Viking Therapeutics is trading at $26.83, up 5.06%, amid strength in the biotech sector.
- XBI is up 2.20%, the clearest available context for the move; broader markets are mixed.
- On October 14, Viking announced it initiated the Phase 3 SUNRISE program for oral VK2735. Available reports do not establish the announcement as the cause of the October 15 rise.